Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
November 20, 2024 16:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2.
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
June 11, 2024 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at...
Global PARP Inhibitor Biomarkers Market to Surpass US$ 2,170.3 Million by 2027, Says CMI
April 13, 2020 11:08 ET
|
CMI
SEATTLE, April 13, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global PARP inhibitor biomarkers market is valued at US$ 374.9 million in 2019, and is projected to exhibit a...